[ad_1]
In addition, Haemonetics believes its commercial and clinical capabilities will increase patient access to OpSens devices and potentially help those devices gain regulatory approvals for new indications.
“With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification,” Stewart Strong, president of the global hospital division at Haemonetics, said in a prepared statement announcing the acquisition. “By leveraging OpSens’ proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top U.S. hospitals performing TAVR and PCI procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide. We are excited to welcome OpSens’ talented team and look forward to advancing our shared commitment to maximizing patient benefits and value for our customers.”
The all-cash transaction is expected to close by January 2024.
Haemonetics created a 10-slide presentation about its acquisition of OpSens. Click here to read the full document.
[ad_2]
Source link